Colorectal cancer is the third most frequently diagnosed cancer in men and women in the United States. An estimated 112,340 new cases of colon cancer will occur in 2007 and an estimated 52,180 people will die from colon and rectal cancer in the same year. Despite these statistics, mortality from colon cancer has decreased over the past 30 years, possibly because of earlier diagnosis through screening and better treatment modalities. These guidelines begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, adjuvant treatment, management of recurrent and metastatic disease, and patient surveillance.
For the most recent version of the guidelines, please visit NCCN.org
If the inline PDF is not rendering correctly, you can download the PDF file here.
Since 1898, Roswell Park Cancer Institute (RPCI), America's first cancer center, has forged an exemplary reputation based on the combined strength of basic/translational research, multidisciplinary oncology teams, educational programs, and compassionate staff. A seamless interface of scientific inquiry and clinical application and an aggressive clinical trials program afford patients access to promising breakthroughs in cancer diagnostics, technology, and therapies.
Over the past decade, RPCI has undergone major renovation and expansion, adding nearly 200 faculty, opening a new hospital facility and a $74 million Center for Genetics & Pharmacology, and forming strategic partnerships with investigators and centers throughout the nation. Committing the infrastructure, intellectual capital, and necessary resources to convert its scientific discoveries into real-world products/applications, RPCI has recently established 3 biotech spin-off companies. RPCI ranks among the nation's top 1% of cancer centers and teaching hospitals for patient satisfaction; and among the top research centers funded by the NCI/NIH.
Donald L. Trump, MD (second picture on the cover), President and CEO, is a practicing medical oncologist and an innovative researcher (his Vitamin D and prostate cancer studies are considered landmark). Dr. Trump was recently elected to the Board of Directors of the Association of American Cancer Institutes. Michael K. K. Wong, MD, PhD, FRCPC (third picture), serves as Medical Director of Clinical Drug Development and Medical Advisor to the Technology Transfer Office, and Kerry J. Rodabaugh, MD (with patient; fourth picture), is with the Department of Gynecologic Oncology.